LONDON - Tuesday, 01. September 2026
(BUSINESS WIRE) -- EMVCo –
the technical body that creates and manages EMV® Specifications and
programmes – has released a draft framework to help promote secure,
interoperable and scalable card-based agentic payments. The framework
provides a foundation for further industry engagement and potential
specification development, with all interested stakeholders encouraged
to provide their feedback on EMV® Agentic Payments – Framework for
Specifications by Wednesday 30 September.
A key focus across the
agentic commerce ecosystem is how to establish intent and determine that
a consumer delegated authority to an AI agent to make a purchase on
their behalf. Following industry input, EMVCo has focused on card-based
agentic payment scenarios where intent needs to be managed over time,
such as recurring purchases, cumulative budgets and post-transaction
activities. These scenarios may require access to a shared intent
‘state’ that persists across multiple participants and their
interactions.
EMVCo has identified an opportunity to complement
cryptographic assurance provided by existing industry solutions, such as
Verifiable Intent, with a common coordination point that can help
participants consistently interpret consumer-authorised intent.
The
draft EMV® Agentic Payments – Framework for Specifications therefore
introduces the concept of ‘Intent Services’. Intent Services provide a
shared, interoperable layer that enables payment participants to
register, reference, retrieve and manage consumer-authorised intent
before, during and after a transaction. The framework provides an
overview of ecosystem roles and data fields for registering intent,
maintaining lifecycle and state information, and enabling the authorised
retrieval of intent-related data.
Junya Tanaka, EMVCo Executive
Committee Chair, comments: “Card-based agentic payments require a
globally interoperable foundation that consumers, merchants and issuers
can all trust. This publication marks an important step forward by
outlining a consistent approach for establishing and communicating
intent alongside payment-related information, and we encourage
participants from across the industry to share their feedback to shape
its ongoing development.”
EMVCo has established a dedicated
Agentic Payments Task Force and is actively engaging with the hundreds
of industry stakeholders that participate as EMVCo Associates and
Subscribers. It is also collaborating closely with various industry
partners and technical bodies, including the FIDO Alliance, the OpenID
Foundation, the OpenWallet Foundation and W3C.
By providing a
common foundation for card-based agentic payments, the framework will
help identify potential future enhancements to other EMV technologies –
including EMV 3-D Secure (3DS), EMV Payment Tokenisation, EMV Secure
Remote Commerce (SRC) and the EMV Digital Payment Credential (DPC). It
will also inform opportunities to complement existing and emerging
identity and credential standards.
Development may also be
required to help enable the consistent identification of agentic
transactions across the payments ecosystem. To support this, EMVCo may
consider capabilities related to Know Your Agent (KYA) and Agentic
Transaction Indicators to be included in future publications. Together,
these could help provide interoperable mechanisms for identifying the
agent involved in a payment interaction, communicating relevant agent
attributes, and signalling that a transaction involved an agent acting
on behalf of a consumer.
Following initial review from EMVCo
Associates, EMV® Agentic Payments – Framework for Specifications is now
available for public review until Wednesday 30 September. As work
continues to progress, all interested stakeholders are encouraged to
explore ways to participate in EMVCo and share input on the strategic
considerations and technical advances shaping agentic payments.
About EMVCo:
EMV®
is a registered trademark in the U.S. and other countries and an
unregistered trademark elsewhere. The EMV trademark is owned by EMVCo,
LLC.
EMVCo creates and manages EMV Specifications and programmes
that enable seamless and secure card-based payments for businesses and
consumers worldwide.
EMV Specifications support technologies
including EMV Contact Chip, EMV Contactless Chip, EMV Mobile, EMV QR
Codes, EMV Secure Remote Commerce, EMV 3-D Secure and EMV Payment
Tokenisation and are widely used by the payments industry to develop
products and services that deliver trusted and convenient in-store,
online and remote card-based payments.
As a global technical
body, EMVCo is collectively owned by American Express, Discover Network,
JCB, Mastercard, UnionPay and Visa. Hundreds of payments stakeholders,
including merchants, banks and technology providers, participate as
EMVCo Associates and Subscribers to develop, evolve and enhance flexible
EMV Specifications that support innovation and address marketplace
needs. All EMV Specifications are available royalty free on the EMVCo
website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831704950/en/
Permalink
https://www.aetoswire.com/en/news/0109202656987
Contacts
david@iseepr.co.uk
Wednesday, September 2, 2026
JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”
(BUSINESS WIRE) -- JEOL Ltd. (President & CEO: Izumi Oi) has developed the benchtop scanning electron microscope (SEM) “JCM-7000Plus” and will begin sales on September 1, 2026.
[Development Background]
Benchtop scanning electron microscopes are increasingly used in fields including electrical and electronics, automotive and machinery, steel and metals, chemical and pharmaceuticals. They are utilized not only in research and development but also in manufacturing-related applications, such as quality control and product inspection. In addition, they are adopted in educational settings at middle and high schools as well as universities. Given these diverse applications, there is growing demand for improved operational efficiency, simpler and more automated operation, and enhanced observation, analysis, and measurement performance.
To meet these needs, we have expanded the landing voltage (accelerating voltage) to 20 kV. This has improved resolution to 6 nm, enabling measurements at higher magnification.
On the software side, the new JCM-7000Plus retains the simple, user-friendly GUI of the current JCM-7000, including Zeromag, which enables a seamless transition from optical imaging to SEM observation, and the Live Analysis function, which allows real-time elemental analysis during observation. It also adds the enhanced automation feature Neo Action.
In addition to the three existing Live functions (Live Analysis, Live Map, and Live 3D), we have added two new features: Live Particle, which automatically measures particle size and count in real time while observing, and Live Report, which automatically acquires data and generates reports while moving the field of view, a feature available in high-end FE-SEMs. These features simplify routine tasks, making them more intuitive and efficient while significantly supporting users' analytical workflows.
[Main Features]
1. Expanding landing voltage to 20 kV for improved resolution (secondary electron image: 6 nm, backscattered electron image: 8 nm)
2. Improved backscattered electron detector for enhanced image quality
3. New Live Particle function automatically measures particle size and count, simplifying workflow
4. Live Report enables data acquisition and report creation while moving the field of view, improving work efficiency
5. Simple and user-friendly GUI retained, with added automation functions for more intuitive and easier operation
[Sales target]
300 units/year
[Related link]
Product Information: JCM-7000Plus NeoScope™ Benchtop SEM
https://www.jeol.com/products/scientific/sem/jcm-7000plus.php
View source version on businesswire.com: https://www.businesswire.com/news/home/20260825564112/en/
Permalink
https://www.aetoswire.com/en/news/0109202656983
Contacts
JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & CEO
(Stock code: 6951, Tokyo Stock Exchange Prime Market)
https://www.jeol.com/
JEOL Ltd.
SI Sales Division
webmaster@jeol.co.jp
https://www.jeol.com/contacts/products.php
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies
(BUSINESS WIRE) -- ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited.
This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-specific technology solutions and full-stack managed services together with Happiest Minds’ strengths in build-led Digital Product Engineering, Data, Cybersecurity, and specialized AI expertise. The proposed combination will lead to a step change in scale for ITCI, enhancing its competitiveness to win large transformation-led mandates and augment capability in critical areas to effectively serve its client base and address new value pools that are emerging with rapid adoption of AI across enterprises. The combined entity will also lead to substantially enhanced presence in the US markets as well as in the Banking, Financial Services and Insurance vertical. Further, key industry segments such as Healthcare, Hitech and Edutech would also get added to ITCI’s portfolio. By adding marquee clients to ITCI’s customer base, the proposed combination will also unlock significant cross-selling & up-selling opportunities.
With a combined global workforce of over 19,000 professionals, it will also deepen complementary capabilities to deliver a full-stack value proposition for end-to-end solutions spanning Build, Intelligence, and Operations whilst expanding into high potential verticals including Hi-Tech, Healthcare and EdTech.
Sanjiv Puri, Chairman of ITC Limited and ITC Infotech, said, "Today marks an important milestone in the journey towards Happiest Minds becoming an integral part of ITC Infotech, subject to receipt of regulatory approvals. The coming together of our complementary strengths, deep domain expertise and future-ready capabilities will further enhance our ability to deliver cutting-edge solutions across geographies. I am particularly encouraged by the shared values, people and customer-centricity that define our organisations. We look forward to the invaluable experience, expertise and dedication of the employees of Happiest Minds as we embark on this exciting new chapter.”
Ashok Soota, Chairman & Chief Mentor, Happiest Minds Technologies, said “I am delighted that after the completion of legal formalities, Happiest Minds will become an important part of a larger organization through its amalgamation with ITC Infotech. The two organizations are aligned on our values and shared vision for the future. There is very significant complementarity in our business portfolios which will ensure synergy. We believe that ITC Infotech is the best partner for Happiest Minds to fulfil its destiny and we are pleased that our team will have a welcoming new home.”
Manas Chakraborty, MD & CEO, ITC Infotech, highlighted that “This combination is fundamentally about elevating the value we deliver to our customers. Integrating Happiest Minds’ Digital Engineering, Data, AI, and Cybersecurity capabilities with our deep domain expertise, cloud and engineering capabilities will enable us to serve as a full stack AI-led transformation partner.”
The proposed transaction is subject to the satisfaction of customary statutory, shareholder and regulatory approvals, including approvals from the Competition Commission of India, the relevant stock exchanges and the National Company Law Tribunal. The companies expect the transaction to be completed within the next 15 months and will continue to operate independently until all approvals have been obtained. Shares of ITC Infotech will be listed on the stock exchanges post receipt of all approvals.
About ITC Infotech:
ITC Infotech is a leading global technology services and solutions provider, led by Business and Technology Consulting. ITC Infotech provides business-friendly solutions to help clients succeed and be future-ready, by seamlessly bringing together digital expertise, strong industry specific alliances and the unique ability to leverage deep domain expertise from ITC Group businesses. The company provides technology solutions and services to enterprises across industries such as Banking & Financial Services, Healthcare, Manufacturing, Consumer Goods, Travel and Hospitality, through a combination of traditional and newer business models, as a long-term sustainable partner.
For more information, please visit: http://www.itcinfotech.com.
About Happiest Minds Technologies Limited:
Happiest Minds Technologies Limited is an AI First, customer-centric digital engineering company committed to delivering ‘Happiest People. Happiest Customers’. With an integrated approach that spans from chip to cloud, Happiest Minds delivers secure and scalable solutions across product engineering, cybersecurity, analytics, and automation platforms. Happiest Minds brings purpose and precision to every engagement, helping enterprises solve complex business challenges and fast-track their digital evolution across industry sectors such as Banking, Financial Services & Insurance(BFSI), EdTech, Healthcare & Life Sciences, Hi-Tech and Media & Entertainment, Industrial, Manufacturing, Energy & Utilities, and Retail, CPG & Logistics.
Happiest Minds has been honored by both the Golden Peacock Awards and the Institute of Company Secretaries of India (ICSI) for its exemplary Corporate Governance practices. Guided by its mission of ‘Happiest People. Happiest Customers’ and consistently recognized as a great place to work, Happiest Minds is headquartered in Bengaluru, India, with a global presence across the Americas, UK, Europe, Australia, the Middle East, Africa, and Asia.
____________________
[1] On a Pro-forma basis
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831399692/en/
Permalink
https://www.aetoswire.com/en/news/0109202656977
Contacts
Nazeeb Arif
nazeeb.Arif@itc.in
Executive Vice President & Head,
Corporate Communications,
ITC Limited
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule
SAN CLEMENTE, Calif. -
(BUSINESS WIRE) -- Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations.
Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.”
“Our main focus is to provide great service to and being a rock-solid partner for our customers. The fact that our profits are growing ahead of plan means we can do even more in product innovation and customer support,” said Fox Hu, Chief Executive Officer of Angel. “We have invested heavily in professional education teams, sales service teams and local clinical support teams that are now producing economies of scale. We appreciate the trust of our customers and the dedication of our employees.”
Reflecting strong profits and robust operating cashflow, Angel’s Board of Directors has declared an interim dividend of US$100 million, underscoring the Company's commitment to delivering superior shareholder returns.
For more detailed information about Angel’s first half 2026 financial results, recent innovations, and go-to-market activities, please see a full description at: https://ir.angelalign.com/en/announcements/.
About Angelalign Technology Inc.
Founded in 2003 and publicly listed since 2021, Angelalign Technology Inc. provides clear aligner solutions to clinically focused professionals and patients in over 60 countries. Having surpassed 2 million cumulative cases and with a US$2 billion market capitalization, the Company focuses on clinical innovation and professional support to help experts achieve extraordinary outcomes. Learn more at angelaligner.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Angelalign undertakes no obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831798503/en/
Permalink
https://www.aetoswire.com/en/news/0109202656975
Contacts
Media Contact:
Sue Kolb
sue.kolb@angelaligner.com
A New Generation of Filmmakers Is Here: 17 Original AI Films from Flick’s Summer Residency
SAN FRANCISCO - Tuesday, 01. September 2026
(BUSINESS WIRE)--What does the Love, Death & Robots look like when a new generation of filmmakers has generative AI at its disposal?
Flick Filmmaker Residency Summer 2026 Cohort offers one possible answer.
The latest cohort brings together established storytellers from the traditional entertainment industry, including a former Disney screenwriter and Emmy Award-winning talent, alongside some of the most distinctive emerging voices in AI filmmaking. Together, they created a collection of original short films spanning science fiction, animation, surrealism, drama, and experimental cinema.
Flick Filmmaker Residency is a selective, two-month program supporting a small cohort of indie filmmakers as they create original films using Flick. The program is free to apply to and includes bi-weekly sessions, creative mentorship, free credits, and early access to new filmmaking tools.
Each resident leaves the program with a festival-ready short film and becomes part of the growing Flick Residency alumni network.
The program is already building a track record on the international festival circuit. Films from Flick’s Spring 2026 cohort have received Official Selections and awards at international film festivals, demonstrating that work created with emerging AI tools can stand on its own as cinema, not simply as a demonstration of the technology behind it.
Watch and Apply
The Summer 2026 Residency films are available to watch on Flick TV at flick.art/showroom.
Applications for the Fall 2026 Flick Filmmaker Residency are now open at flick.art/residency.
The Filmmaker Still Matters
The rapid development of generative video raises a larger question for cinema: if increasingly powerful models can produce beautiful images, what becomes valuable?
“Story matters. Editing matters. Performance matters. Sound matters. And above all, the filmmaker’s ability to make decisions matters,” said Zoey Zhang, Co-Founder of Flick.
The technology may be shared.
The films are not.
As generative tools become more powerful and more accessible, Flick believes the defining question of AI filmmaking will increasingly shift from what can the technology generate? to what does the filmmaker choose to do with it?
The Summer 2026 Residency offers an early glimpse of that future: not a collection of AI demos, but authentic stories shaped by the filmmakers behind them.
About Flick
Founded by Zoey Zhang and Ray Wang, Flick is an AI-native filmmaking platform built for creators who care about aesthetics, control, and creative flexibility. The product enables filmmakers to direct AI-generated films through non-linear workflows, cinematic controls, and iterative creative tools — bridging powerful generative models with real-world filmmaking. Flick also operates Flick Filmmaker Residency, an initiative to cultivate the next generation of AI-native filmmakers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260901631989/en/
Permalink
https://www.aetoswire.com/en/news/1092026569922
Contacts
Flick Team
Email: contact@flick.art
Website: https://flick.art
Rigaku Launches CT Lab HR160 High-Resolution X-ray CT System
- Developed in collaboration with Excillum for battery, semiconductor devices, and advanced materials analysis -
(BUSINESS WIRE)--Rigaku Corporation, a global solutions partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (Headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), today announced the launch of the CT Lab HR160, a high-resolution X-ray computed tomography (CT) system for battery, semiconductor devices, electronic components, and advanced materials analysis. The system is developed in collaboration with Excillum AB, the global source for X-ray innovation (Headquarters: Stockholm, Sweden; CEO: David Lindblom; “Excillum”).
CT Lab HR160 combines Rigaku’s X-ray CT imaging expertise with Excillum’s NanoTube N3 X-ray source. Operating at up to 160 kV to support a wide range of sample types, the system achieves true 250 nm spatial resolution — an industry-leading level for CT systems in its class. This enables detailed, non-destructive 3D imaging of fine internal structures and defects that can be difficult to observe with conventional laboratory CT systems.
Its cone-beam geometry allows users to adjust the field of view and resolution without changing the X-ray source, detector, simplifying operation across different samples and imaging requirements. The system is designed for applications such as solid-state batteries, semiconductor devices, multilayer ceramic capacitors (MLCCs), and power electronics, where internal inspection plays an increasingly important role in research, development, quality evaluation, and failure analysis.
As electronic components and advanced materials become smaller, more complex, and higher-performing, researchers and manufacturers need analytical tools that can reveal increasingly fine internal features with greater precision. Built on the combined strengths of Rigaku and Excillum, CT Lab HR160 addresses these needs by providing a high-resolution laboratory CT environment that supports faster development, improved product quality, and more advanced failure analysis.
“CT Lab HR160 gives customers a new option for addressing increasingly complex analytical challenges in advanced materials and electronic devices. By providing high-resolution CT capabilities in a laboratory environment, we aim to support faster decision-making across research, development, quality evaluation, and failure analysis,” said Kiyoshi Ogata, General Manager of the Product Division, Rigaku.
“We are pleased to see Excillum’s X-ray source technology integrated into Rigaku’s new CT Lab HR160 system. This collaboration brings together the strengths of both companies and creates new opportunities to support R&D and manufacturing at the forefront of advanced industries,” said Sara Haack, Chief Commercial Officer, Excillum AB.
Additional information about CT Lab HR160 is available on the Rigaku website:
Rigaku CT Lab HR160 product page
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in 136 countries and regions and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit: rigaku-holdings.com/english
About Excillum
Excillum is the global source for X-ray innovation. We develop, manufacture, and service the world’s brightest and most advanced industrial and laboratory X-ray sources. In close collaboration with best-in-class scientific, industrial and system integration partners we enable new science, improve medicine and enhance manufacturing. Headquartered in Stockholm, Sweden, Excillum is pushing the limits of X-ray source technologies since 2007. excillum.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260901074099/en/
Permalink
https://www.aetoswire.com/en/news/1092026569977
Contacts
Press Contact:
Sawa Himeno
Director, Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
Sara Haack, Chief Commercial Officer
sara.haack@excillum.com
+46 721 436 983
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
SAN CARLOS, Calif. - Tuesday, 01. September 2026 AETOSWire
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing
(BUSINESS WIRE) -- BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation.
John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said:
“At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.”
Improved access to oncology medicines for patients
This announcement reflects BeOne’s participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model and the company’s commitment to pricing future FDA-approved products in line with other key developed markets.
Increased manufacturing and investment
Through continued investments in U.S. manufacturing, BeOne is enhancing supply continuity and manufacturing flexibility while supporting patient access to innovative medicines.
BeOne entered into an onshoring agreement with the U.S. government, securing an exemption from Section 232 pharmaceutical tariffs that recognizes the company’s significant and ongoing investments in US. manufacturing.
The company recently announced a $300 million onshoring investment in its flagship clinical and commercial-stage manufacturing and research and development facility in Hopewell, NJ, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will add small-molecule manufacturing capacity, create approximately 120 full-time jobs and enhance BeOne’s ability to manufacture medicines in the states and advance its oncology pipeline of more than 35 clinical- and commercial-stage assets.
The U.S. is an important hub for BeOne's scientific, clinical and manufacturing operations. BeOne employs more than 2,000 U.S. colleagues within a global team of more than 12,000 across six continents. In 2025, the company generated nearly $2 billion in direct U.S. economic impact and invested $1 billion in U.S. research and development. BeOne is also advancing one of oncology's broadest pipelines through 93 clinical trials at approximately 1,100 sites across 45 states and one territory, supported by more than 650 investigators.
About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne helping more eligible patients in the U.S. access innovative cancer medicines while supporting continued investment in U.S. research, manufacturing and scientific innovation; BeOne reaching patients around the world faster, more reliably and at greater scale; BeOne pricing future FDA-approved products in line with other key developed markets; BeOne’s commitment to continued investment in U.S. manufacturing, stronger supply chain resilience, and support of patient access to innovative medicines; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
To access BeOne media resources, please visit our Newsroom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831047788/en/
Permalink
https://www.aetoswire.com/en/news/0109202656974
Contacts
Investor Contact
Liza Heapes
+1 857-302-5663
ir@beonemed.com
Media Contact
Kyle Blankenship
+ 1 667-351-5176
media@beonemed.com
Subscribe to:
Posts (Atom)